Venous thromboembolism risk in patients with hormone receptor-positive HER2-negative metastatic breast cancer treated with combined CDK 4/6 inhibitors plus endocrine therapy versus endocrine therapy alone: a systematic review and meta-analysis of randomized controlled trials

被引：0
作者：
Kyaw Zin Thein
Thura Win Htut
Somedeb Ball
Sriman Swarup
Anita Sultan
Thein Hlaing Oo
机构：
[1] The University of Texas MD Anderson Cancer Center,Department of Investigational Cancer Therapeutics
[2] University of Aberdeen,Department of Hematology, Aberdeen Royal Infirmary Hospital
[3] Texas Tech University Health Sciences Center,Department of Internal Medicine
[4] Texas Tech University Health Sciences Center,Department of Hematology/Oncology
[5] The University of Texas MD Anderson Cancer Center,Section of Benign Hematology
来源：
Breast Cancer Research and Treatment | 2020年 / 183卷
关键词：
Metastatic breast cancer; Venous thromboembolism; Hormone receptor-positive HER2-negative; Meta-analysis;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：479 / 487
页数：8
相关论文
共 50 条
  • [1] Venous thromboembolism risk in patients with hormone receptor-positive HER2-negative metastatic breast cancer treated with combined CDK 4/6 inhibitors plus endocrine therapy versus endocrine therapy alone: a systematic review and meta-analysis of randomized controlled trials
    Thein, Kyaw Zin
    Htut, Thura Win
    Ball, Somedeb
    Swarup, Sriman
    Sultan, Anita
    Oo, Thein Hlaing
    BREAST CANCER RESEARCH AND TREATMENT, 2020, 183 (02) : 479 - 487
  • [2] Efficacy and safety of CDK4/6 inhibitors combined with endocrine therapy versus endocrine therapy alone in hormone receptor-positive, HER2-negative, advanced breast cancer: a systematic review and meta-analysis
    Dai, Qiuying
    Wang, Yongling
    Liao, Mingjuan
    Chen, Hongfeng
    ANNALS OF PALLIATIVE MEDICINE, 2022, : 3727 - 3742
  • [3] Comparative Overall Survival of CDK4/6 Inhibitors Plus Endocrine Therapy vs. Endocrine Therapy Alone for Hormone receptor-positive, HER2-negative metastatic breast cancer
    Lin, Mingxi
    Chen, Yang
    Jin, Yizi
    Hu, Xichun
    Zhang, Jian
    JOURNAL OF CANCER, 2020, 11 (24): : 7127 - 7136
  • [4] CDK4/6 inhibitors in advanced hormone receptor-positive/HER2-negative breast cancer: a systematic review and meta-analysis of randomized trials
    Carlo Messina
    Carlo Cattrini
    Giulia Buzzatti
    Luigi Cerbone
    Elisa Zanardi
    Marco Messina
    Francesco Boccardo
    Breast Cancer Research and Treatment, 2018, 172 : 9 - 21
  • [5] CDK4/6 inhibitors in advanced hormone receptor-positive/HER2-negative breast cancer: a systematic review and meta-analysis of randomized trials
    Messina, Carlo
    Cattrini, Carlo
    Buzzatti, Giulia
    Cerbone, Luigi
    Zanardi, Elisa
    Messina, Marco
    Boccardo, Francesco
    BREAST CANCER RESEARCH AND TREATMENT, 2018, 172 (01) : 9 - 21
  • [6] First-line endocrine therapy for postmenopausal patients with hormone receptor-positive, HER2-negative metastatic breast cancer: a systematic review and meta-analysis
    Shimoi, Tatsunori
    Sagara, Yasuaki
    Hara, Fumikata
    Toyama, Tatsuya
    Iwata, Hiroji
    BREAST CANCER, 2020, 27 (03) : 340 - 346
  • [7] Endocrine therapy for hormone receptor-positive, HER2-negative metastatic breast cancer: extending endocrine sensitivity
    Frassoldati, Antonio
    Biganzoli, Laura
    Bordonaro, Roberto
    Cinieri, Saverio
    Conte, Pierfranco
    De Laurentis, Michelino
    Del Mastro, Lucia
    Gori, Stefania
    Lauria, Rossella
    Marchetti, Paolo
    Michelotti, Andrea
    Montemurro, Filippo
    Naso, Giuseppe
    Pronzato, Paolo
    Puglisi, Fabio
    Tondini, Carlo Alberto
    FUTURE ONCOLOGY, 2020, 16 (05) : 129 - 145
  • [8] First-line endocrine therapy for postmenopausal patients with hormone receptor-positive, HER2-negative metastatic breast cancer: a systematic review and meta-analysis
    Tatsunori Shimoi
    Yasuaki Sagara
    Fumikata Hara
    Tatsuya Toyama
    Hiroji Iwata
    Breast Cancer, 2020, 27 : 340 - 346
  • [9] CDK4/6 inhibitor plus endocrine therapy for hormone receptor-positive, HER2-negative metastatic breast cancer: The new standard of care
    Hui, Rina
    de Boer, Richard
    Lim, Elgene
    Yeo, Belinda
    Lynch, Jodi
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2021, 17 : 3 - 14
  • [10] Adjuvant CDK4/6 inhibitors combined with endocrine therapy in HR-positive, HER2-negative early breast cancer: A meta-analysis of randomized clinical trials
    Gao, Hong-Fei
    Lin, Ying-Yi
    Zhu, Teng
    Ji, Fei
    Zhang, Liu-Lu
    Yang, Ci-Qiu
    Yang, Mei
    Li, Jie-Qing
    Cheng, Min-Yi
    Wang, Kun
    BREAST, 2021, 59 : 165 - 175
12345